- 2024-08-20 02:07抑制剂Parsaclisib hydrochloride|Parsaclisib hydrochloride|1995889-48-9|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:07抑制剂Parsaclisib hydrochloride|Parsaclisib hydrochloride|1995889-48-9|Adamas life|≥98%（以实测数值为准）|BR|25m
- 2024-08-20 02:07抑制剂Pacritinib|Pacritinib|937272-79-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂Pacritinib|Pacritinib|937272-79-2|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:07抑制剂Pam3CSK4 TFA|Pam3CSK4 TFA|112208-01-2|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:07抑制剂Pam3CSK4 TFA|Pam3CSK4 TFA|112208-01-2|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂PA-8|PA-8|878437-15-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂PA-8|PA-8|878437-15-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:07抑制剂Pacritinib|Pacritinib|937272-79-2|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:07抑制剂p38 MAPK-IN-4|p38 MAPK-IN-4|219138-24-6|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂p38 MAPK-IN-4|p38 MAPK-IN-4|219138-24-6|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:07抑制剂PA-8|PA-8|878437-15-1|Adamas life|≥98%（以实测数值为准）|BR|100mg
- 2024-08-20 02:07抑制剂Oxysanguinarine|Oxysanguinarine|548-30-1|Adamas life|≥98%（以实测数值为准）|BR|5mg
- 2024-08-20 02:07抑制剂p38 MAPK-IN-4|p38 MAPK-IN-4|219138-24-6|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:07抑制剂Oxomemazine|Oxomemazine|3689-50-7|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂Oxomemazine|Oxomemazine|3689-50-7|Adamas life|≥98%（以实测数值为准）|BR|500mg
- 2024-08-20 02:07抑制剂Oxysanguinarine|Oxysanguinarine|548-30-1|Adamas life|≥98%（以实测数值为准）|BR|1mg
- 2024-08-20 02:07抑制剂Oxysanguinarine|Oxysanguinarine|548-30-1|Adamas life|≥98%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂OUL35|OUL35|6336-34-1|Adamas life|≥97%（以实测数值为准）|BR|25mg
- 2024-08-20 02:07抑制剂OUL35|OUL35|6336-34-1|Adamas life|≥97%（以实测数值为准）|BR|5mg
